Clinical trials: Prostate-Specific Antigen
Prostate Cancer Patients Undergoing Radical Prostatectomy, Prostate CA
Research on PSMA-Targeted Intraoperative Fluorescent Imaging Agents
Phase I: Primary Research Objective: Evaluate the safety, tolerability, and pharmacokinetic characteristics of a single dose of DGPR1008 in healthy subjects.
- Trial name
- DGPR1008 (NCT07101354)
- Testing
- 0.01mg/kg DGPR1008 Injection Dose Group 1 (n=6), 0.02mg/kg DGPR1008 Injection Dose Group 2 (n=6), 0.04mg/kg DGPR1008 Injection Dose Group 3 (n=6)
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Haitao Niu, MD
Prostate Cancer
Combined Prostate-specific Antigen, Multi-parametric MRI and Targeted Prostate Biopsy for Prostate Cancer Screening
The study aims to investigate the incidence of prostate cancer among males in Nanjing and whether a combination of PSA, multi-parametric MRI and targeted biopsy is a feasible approach for screening prostate cancer in China.
- Trial name
- NCT04322045
- Testing
- multi-parametric MRI
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Dissemination of Prostate Cancer Screening to PCP's in African American Communities
The aims of this project are to adapt and extend the use of academic detailing to the dissemination of prostate cancer (CaP) screening findings to primary care physicians practicing in African American communities.
- Trial name
- NCT00629330
- Testing
- Academic Detailing
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Columbia University
PSA, Prostate Cancer
Smart Prostate Specific Antigen (PSA) Screening Study
This intervention includes the introduction of the Prostate Cancer Working Group (PCWG )Smart PSA Screening Guidelines and implementation of patient navigation/ care coordination for men with elevated PSA (>4.0 ng/mL).
- Trial name
- NCT04782713
- Testing
- Completing surveys
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Prostate Carcinoma
Prostate Specific Antigen Levels of Individuals Living in Rural Areas
It was planned in cross-sectional design in order to determine the specific prostate antigen level and some characteristics and the relationship evaluations and prostate specific antigen formation in individuals living in rural…
- Trial name
- NCT06900348
- Testing
- PSA-Activated PSA-PAH1
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Suleyman Demirel University
Prostatic Neoplasms, Recurrence
PSMA PET/CT for Biochemical Recurrence Detection in Patients With Prostate Cancer
The aim of this study is to evaluate PSMA-PET for the detection of occult biological recurrence in patients with prostatic cancer referred to the Brest University Hospital.
- Trial name
- RB-PSMA (NCT04983459)
- Where
- France
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Prostate Cancer
Comparison Of Effectiveness of Transrectal Ultrasonography-Guided Saturation Biopsy And 10-12 Core Biopsy In Repeated Prostate Biopsies
OBJECTIVE To assessment the results of repeated saturation and 10-12 core biopsy protocols in patients with a negative initial biopsy but continued suspicion for prostate cancer MATERIALS AND METHOD Data of the patients who…
- Trial name
- NCT01827813
- Testing
- Transrectal prostate biopsy with ultrasonography., Periprostatic block, Sedoanalgesia
- Where
- Turkey (Türkiye)
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
Prostate Cancer
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects…
- Trial name
- NCT03995888
- Testing
- rhPSMA-7.3 (18F) Injection
- Where
- Finland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer
Screening for Prostate Cancer Among Those Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mL
The study aims to evaluate the detection rate and characteristics of prostate cancer among males with PSA values between 2.5 and 4.0 ng/mL in Nanjing, meanwhile, to access the effectiveness of conducting multi-parametric MRI…
- Trial name
- NCT04317625
- Testing
- mpMRI scanning
- Where
- China
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
The primary objective of this study is to evaluate the effect of erlotinib on the PSA response rate in patients with non-metastatic prostate cancer and a rising PSA on androgen deprivation therapy.
- Trial name
- NCT00148772
- Testing
- Erlotinib (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Prostatic Neoplasms
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer
Prostate cancer (PCa) is the most common type of malignant tumor and the third leading cause of cancer-associated mortality among men worldwide.
- Trial name
- NCT04521894
- Testing
- Positron emission tomography/computerized tomography (PET/CT)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer, PSA
PSA Glycomics Assay for Early Detection of Prostate Cancer
The principal aim of this pilot study is to test whether the PSA Glycomics Assay on urine and serum samples can provide insights regarding the disease state of patients with elevated PSA concentrations, as well as to accurately…
- Trial name
- NCT04393376
- Testing
- PSA Glycomics Assay
- Where
- 3 sites in Netherlands
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Prof.dr. H.P. Beerlage
Prostate Cancer
The ProCaRis Study: Prostate Cancer Risk Assessment in General Practice
The preferred method for early detection of prostate cancer (PCa) in older men with family history is the Prostate Specific Antigen test (PSA test), although the method is imprecise.
- Trial name
- ProCaRis (NCT01739062)
- Testing
- Genetic risk assessment
- Where
- Denmark
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of Aarhus